Back to top
more

Amylyx Pharmaceuticals (AMLX)

(Delayed Data from NSDQ)

$7.03 USD

7.03
2,000,629

+0.33 (4.93%)

Updated Nov 11, 2024 04:00 PM ET

After-Market: $7.04 +0.01 (0.14%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (69 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Minerva (NERV) Down; FDA Denies Review Schizophrenia Drug NDA

by Zacks Equity Research

Minerva (NERV) confirmed that the FDA's refuse-to-file letter on its regulatory filing, seeking approval for roluperidone, to treat symptoms of schizophrenia remains in effect.

Biohaven Pharma's (BHVN) ALS Study Fail to Meet Both Endpoints

by Zacks Equity Research

Biohaven Pharmaceuticals (BHVN) suffers a setback as verdiperstat fails to meet the primary and secondary endpoints in an ALS study.

Amylyx (AMLX) Secures the FDA's Approval for ALS Drug

by Zacks Equity Research

Amylyx (AMLX) obtains the FDA's approval for its oral, fixed-dose combination therapy for treating adults with amyotrophic lateral sclerosis (ALS) after a few roadblocks.

Biotech Stock Roundup: BMY Surges on Drug Approval, REGN Up on Update & More

by Zacks Equity Research

Regulatory and pipeline updates from BMY and REGN are the key highlights from the biotech sector during the past week.

Amylyx (AMLX) Up 51% After FDA Committee Endorses ALS Drug

by Zacks Equity Research

The FDA's PCNSDAC recommends granting marketing approval to Amylyx's (AMLX) oral drug, which slows the progression of ALS.

Is a Surprise Coming for Amylyx Pharmaceuticals (AMLX) This Earnings Season?

by Zacks Equity Research

Amylyx Pharmaceuticals (AMLX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

    Biotech Stock Roundup: VRTX's Regulatory Update, TYME Gains on Acquisition & More

    by Zacks Equity Research

    Regulatory and other updates from Vertex (VRTX) and TYME are a few key highlights from the biotech sector during the past week.

    Molina Healthcare (MOH) to Post Q1 Earnings: What's in Store?

    by Zacks Equity Research

    Molina Healthcare's (MOH) first-quarter results are likely to reflect the benefits of increased membership in the Medicare program.

    Teladoc (TDOC) Eyes Q1 Earnings Beat on Rising US Paid Members

    by Zacks Equity Research

    Teladoc Health's (TDOC) first-quarter 2022 results are likely to reflect improved subscription access fees revenues.